The pharmaceutical giant Moderna expressed optimism that its new flu shot will be available this year after the FDA accepted its revised application for approval. The new vaccine is aimed at patients aged 50-64, with expedited approval for those over 65. The FDA’s decision to review the application marks a reversal from its earlier denial, sparking concerns in the industry about vaccine reception under the Trump administration.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
